预约演示

Privo Technologies, Inc. Awarded $2M Direct-to-Phase II Contract from the National Cancer Institute Cancer Institute for PRV311 Treatment of Cervical Cancer

2022-09-09

PEABODY, Mass., Sept. 9, 2022 /PRNewswire/ -- Privo Technologies, Inc. ("Privo", "the Company") announced today that it has been awarded a $2M Direct-to-Phase II SBIR Contract from the National Cancer Institute (NCI)Cancer Institute (NCI), part of the National Institutes of Health. The contract will be used to further the development of PRV311, Privo's third lead asset, for the treatment of cervical cancer in low resource settings.

PRV311 Promises to Treat Cervical Cancer while Preserving Reproductive Function

PRV311al cancer has high Cervical Cancerow- and middle-income countries (LMICs) and remains the leading cause of cancer death among women despite the remarkable improvements in prevention seen in wealthier countries. Privo intends to bridge this healthcare gap with PRV311, a nanoengineered localized treatment applied directly to cervical tumors. Utilizing the funds from the contract, Privo aims to complete clinical trial preparation activities to validate the PRV311 cancer treatment. This treatment has the potential to minimize surgery, reduce the risk of preterm birth, and reduce the extent of disfigurement.

Cervical cancertted to changing the paradigm of cancer treatment, with a special focus on mucosal solid tumors. Wcancergrateful to the NCI for their support in expanding the PRV platform into further indications," saiPrivo Manijeh Goldberg, Ph.D., CEO and Founder. "PRV311has focused on epithelial cancers and as a result has succecervical tumorsits PRV111 treatment to the pivotal trialPrivoe for head and neck cancers."PRV311 PRV311 cancer

PRV311 is a derivative of the PRV platform desigcancerr the treatment of cervical and othemucosal solid tumorsre controlled and sustained release of chemotherapeutics ideal for use in low-resource settings. This will enable fewer treatment visits and applications required to reach a theepithelial cancersss of patients to follow-up in low-resource sPRV111s is one of the greatest obstacles to effehead and neck cancerst. By providing a long-lasting treatment alternative for patients with cervical cancer, PRV311 can address this disparity and potentially change the treatment of cervical cancer globally," said Dr. Goldberg.

PRV311roject is funded in part with Federal funds from the National Cancecervical and other cancersitutes of Health, Department of Health and Human Services, under Contract No. 75N91022C00020.cancer cervical cancer PRV311 cervical cancer

About Privo Technologies, Inc.National Cancer Institute Cancer National Institutes of Health

Privo Privo Technologies, Inc.o) is a phase 3 clinical-stage biopharmaceutical company committed to developing innovative therapeutics designed to eliminate cancers and prevent recurrence. Privo aims to provide better and more accessible treatment options to diverse patient populations around the world with the potential to transform standard of care for treating solid tumors. Privo is headquartered in Peabody, a suburb of Boston, Massachusetts. For more information on the technology see Privo's most recent publication (https://www.nature.com/articles/s41467-022-31859-3), described in detail in Forbes: Disruptive Innovation In Drug Delivery Systems.

Privo Technologies, Inc.11Privobeen shown to be effective in patients with head and neck cancer in several hospitals across the US during a safety and efficacancerse I/II clinical study, drPrivocally reducing tumor volume without any systemic toxicity. For additional information on Privo Technologies, Inc. please visit www.privotechnologies.com.solid tumors Privo Privo